Analysts Are Bullish on These Healthcare Stocks: Alphatec Holdings (ATEC), Terns Pharmaceuticals (TERN)

view original post

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alphatec Holdings (ATECResearch Report), Terns Pharmaceuticals (TERNResearch Report) and Aerovate Therapeutics (AVTEResearch Report) with bullish sentiments.

Alphatec Holdings (ATEC)

In a report issued on May 8, Josh Jennings from TD Cowen maintained a Buy rating on Alphatec Holdings, with a price target of $22.50. The company’s shares closed last Monday at $11.14.

According to TipRanks.com, Jennings is a 4-star analyst with an average return of 6.8% and a 51.7% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Zimmer Biomet Holdings, and Tandem Diabetes Care.

Alphatec Holdings has an analyst consensus of Strong Buy, with a price target consensus of $23.17, representing a 100.6% upside. In a report issued on May 7, Canaccord Genuity also maintained a Buy rating on the stock with a $25.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Terns Pharmaceuticals (TERN)

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Terns Pharmaceuticals. The company’s shares closed last Monday at $5.89.

According to TipRanks.com, Baral is a 4-star analyst with an average return of 6.6% and a 43.5% success rate. Baral covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Praxis Precision Medicines, and Milestone Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Terns Pharmaceuticals with a $14.92 average price target, a 159.5% upside from current levels. In a report issued on April 30, JMP Securities also maintained a Buy rating on the stock with a $15.00 price target.

Aerovate Therapeutics (AVTE)

TD Cowen analyst Joseph Thome maintained a Buy rating on Aerovate Therapeutics today. The company’s shares closed last Monday at $19.14.

According to TipRanks.com, Thome is a 1-star analyst with an average return of -2.0% and a 43.4% success rate. Thome covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Entrada Therapeutics Inc, and Third Harmonic Bio, Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aerovate Therapeutics with a $50.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ATEC: